Treatment with levodopa and risk for malignant melanoma.
Identifieur interne : 001C55 ( Ncbi/Merge ); précédent : 001C54; suivant : 001C56Treatment with levodopa and risk for malignant melanoma.
Auteurs : J Rgen H. Olsen [Danemark] ; Karina Tangerud ; Lene Wermuth ; Kirsten Frederiksen ; S Ren FriisSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2007.
English descriptors
- KwdEn :
- Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Case-Control Studies, Female, Follow-Up Studies, Humans, Incidence, Levodopa (adverse effects), Levodopa (therapeutic use), Male, Melanoma (complications), Melanoma (epidemiology), Odds Ratio, Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson Disease (epidemiology), Retrospective Studies, Risk.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- complications : Melanoma, Parkinson Disease.
- drug therapy : Parkinson Disease.
- epidemiology : Melanoma, Parkinson Disease.
- Case-Control Studies, Female, Follow-Up Studies, Humans, Incidence, Male, Odds Ratio, Retrospective Studies, Risk.
Abstract
A large follow-up study in Denmark of 14,088 patients in whom Parkinson's disease was diagnosed at hospital showed a twofold higher incidence of malignant melanoma in these patients than in the general population. In a nested case-control study of 45 patients with malignant melanoma, 97 patients with nonmelanoma skin cancer, and 172 control subjects, we investigated the hypothesis that treatment with levodopa increases the risk for skin cancer. Information on diagnoses and treatment was retrieved from medical records. We observed a significant fourfold to fivefold increase in the risk for malignant melanoma in a subgroup of patients with a probable diagnosis of idiopathic Parkinson's disease as compared with other patients. There was apparently no effect of levodopa on the risk for malignant melanoma as indicated by an odds ratio of 1.0 (95% confidence interval, 0.8-1.3) per 1,000 g cumulative intake of the drug. We conclude that the increased rate of malignant melanoma observed in patients treated at hospital for Parkinson's disease is restricted to those with idiopathic Parkinson's disease, however, unrelated to the treatment with levodopa.
DOI: 10.1002/mds.21397
PubMed: 17534943
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002684
- to stream PubMed, to step Curation: 002684
- to stream PubMed, to step Checkpoint: 002495
Links to Exploration step
pubmed:17534943Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment with levodopa and risk for malignant melanoma.</title><author><name sortKey="Olsen, J Rgen H" sort="Olsen, J Rgen H" uniqKey="Olsen J" first="J Rgen H" last="Olsen">J Rgen H. Olsen</name><affiliation wicri:level="3"><nlm:affiliation>Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark. jorgen@cancer.dk</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen</wicri:regionArea><placeName><settlement type="city">Copenhague</settlement><region type="région" nuts="2">Hovedstaden</region></placeName></affiliation></author><author><name sortKey="Tangerud, Karina" sort="Tangerud, Karina" uniqKey="Tangerud K" first="Karina" last="Tangerud">Karina Tangerud</name></author><author><name sortKey="Wermuth, Lene" sort="Wermuth, Lene" uniqKey="Wermuth L" first="Lene" last="Wermuth">Lene Wermuth</name></author><author><name sortKey="Frederiksen, Kirsten" sort="Frederiksen, Kirsten" uniqKey="Frederiksen K" first="Kirsten" last="Frederiksen">Kirsten Frederiksen</name></author><author><name sortKey="Friis, S Ren" sort="Friis, S Ren" uniqKey="Friis S" first="S Ren" last="Friis">S Ren Friis</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="doi">10.1002/mds.21397</idno><idno type="RBID">pubmed:17534943</idno><idno type="pmid">17534943</idno><idno type="wicri:Area/PubMed/Corpus">002684</idno><idno type="wicri:Area/PubMed/Curation">002684</idno><idno type="wicri:Area/PubMed/Checkpoint">002495</idno><idno type="wicri:Area/Ncbi/Merge">001C55</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Treatment with levodopa and risk for malignant melanoma.</title><author><name sortKey="Olsen, J Rgen H" sort="Olsen, J Rgen H" uniqKey="Olsen J" first="J Rgen H" last="Olsen">J Rgen H. Olsen</name><affiliation wicri:level="3"><nlm:affiliation>Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark. jorgen@cancer.dk</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen</wicri:regionArea><placeName><settlement type="city">Copenhague</settlement><region type="région" nuts="2">Hovedstaden</region></placeName></affiliation></author><author><name sortKey="Tangerud, Karina" sort="Tangerud, Karina" uniqKey="Tangerud K" first="Karina" last="Tangerud">Karina Tangerud</name></author><author><name sortKey="Wermuth, Lene" sort="Wermuth, Lene" uniqKey="Wermuth L" first="Lene" last="Wermuth">Lene Wermuth</name></author><author><name sortKey="Frederiksen, Kirsten" sort="Frederiksen, Kirsten" uniqKey="Frederiksen K" first="Kirsten" last="Frederiksen">Kirsten Frederiksen</name></author><author><name sortKey="Friis, S Ren" sort="Friis, S Ren" uniqKey="Friis S" first="S Ren" last="Friis">S Ren Friis</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Case-Control Studies</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Incidence</term><term>Levodopa (adverse effects)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Melanoma (complications)</term><term>Melanoma (epidemiology)</term><term>Odds Ratio</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (epidemiology)</term><term>Retrospective Studies</term><term>Risk</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Melanoma</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Melanoma</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Case-Control Studies</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Incidence</term><term>Male</term><term>Odds Ratio</term><term>Retrospective Studies</term><term>Risk</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A large follow-up study in Denmark of 14,088 patients in whom Parkinson's disease was diagnosed at hospital showed a twofold higher incidence of malignant melanoma in these patients than in the general population. In a nested case-control study of 45 patients with malignant melanoma, 97 patients with nonmelanoma skin cancer, and 172 control subjects, we investigated the hypothesis that treatment with levodopa increases the risk for skin cancer. Information on diagnoses and treatment was retrieved from medical records. We observed a significant fourfold to fivefold increase in the risk for malignant melanoma in a subgroup of patients with a probable diagnosis of idiopathic Parkinson's disease as compared with other patients. There was apparently no effect of levodopa on the risk for malignant melanoma as indicated by an odds ratio of 1.0 (95% confidence interval, 0.8-1.3) per 1,000 g cumulative intake of the drug. We conclude that the increased rate of malignant melanoma observed in patients treated at hospital for Parkinson's disease is restricted to those with idiopathic Parkinson's disease, however, unrelated to the treatment with levodopa.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">17534943</PMID><DateCreated><Year>2007</Year><Month>07</Month><Day>30</Day></DateCreated><DateCompleted><Year>2008</Year><Month>04</Month><Day>16</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>9</Issue><PubDate><Year>2007</Year><Month>Jul</Month><Day>15</Day></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Treatment with levodopa and risk for malignant melanoma.</ArticleTitle><Pagination><MedlinePgn>1252-7</MedlinePgn></Pagination><Abstract><AbstractText>A large follow-up study in Denmark of 14,088 patients in whom Parkinson's disease was diagnosed at hospital showed a twofold higher incidence of malignant melanoma in these patients than in the general population. In a nested case-control study of 45 patients with malignant melanoma, 97 patients with nonmelanoma skin cancer, and 172 control subjects, we investigated the hypothesis that treatment with levodopa increases the risk for skin cancer. Information on diagnoses and treatment was retrieved from medical records. We observed a significant fourfold to fivefold increase in the risk for malignant melanoma in a subgroup of patients with a probable diagnosis of idiopathic Parkinson's disease as compared with other patients. There was apparently no effect of levodopa on the risk for malignant melanoma as indicated by an odds ratio of 1.0 (95% confidence interval, 0.8-1.3) per 1,000 g cumulative intake of the drug. We conclude that the increased rate of malignant melanoma observed in patients treated at hospital for Parkinson's disease is restricted to those with idiopathic Parkinson's disease, however, unrelated to the treatment with levodopa.</AbstractText><CopyrightInformation>2007 Movement Disorder Society</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Olsen</LastName><ForeName>Jørgen H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark. jorgen@cancer.dk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tangerud</LastName><ForeName>Karina</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Wermuth</LastName><ForeName>Lene</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Frederiksen</LastName><ForeName>Kirsten</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Friis</LastName><ForeName>Søren</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016022">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015994">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008545">Melanoma</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016017">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D012306">Risk</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>5</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>4</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>5</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.21397</ArticleId><ArticleId IdType="pubmed">17534943</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Danemark</li></country><region><li>Hovedstaden</li></region><settlement><li>Copenhague</li></settlement></list><tree><noCountry><name sortKey="Frederiksen, Kirsten" sort="Frederiksen, Kirsten" uniqKey="Frederiksen K" first="Kirsten" last="Frederiksen">Kirsten Frederiksen</name><name sortKey="Friis, S Ren" sort="Friis, S Ren" uniqKey="Friis S" first="S Ren" last="Friis">S Ren Friis</name><name sortKey="Tangerud, Karina" sort="Tangerud, Karina" uniqKey="Tangerud K" first="Karina" last="Tangerud">Karina Tangerud</name><name sortKey="Wermuth, Lene" sort="Wermuth, Lene" uniqKey="Wermuth L" first="Lene" last="Wermuth">Lene Wermuth</name></noCountry><country name="Danemark"><region name="Hovedstaden"><name sortKey="Olsen, J Rgen H" sort="Olsen, J Rgen H" uniqKey="Olsen J" first="J Rgen H" last="Olsen">J Rgen H. Olsen</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C55 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001C55 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:17534943
|texte= Treatment with levodopa and risk for malignant melanoma.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:17534943" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |